Urological medical oncology: land of opportunity

Jones, R. (2013) Urological medical oncology: land of opportunity. Future Oncology, 9(2), pp. 149-152. (doi: 10.2217/FON.12.176)

Full text not currently available from Enlighten.

Abstract

Robert Jones speaks to Francesca Lake, Managing Commissioning Editor. Robert completed his PhD in molecular biology at the Beatson Institute for Cancer Research (Glasgow, UK) and is currently the senior lecturer in medical oncology at the University of Glasgow (UK) and a consultant at the Beatson West of Scotland Cancer Centre (Glasgow, UK). He is involved in the management of prostate, bladder and kidney cancers in the clinic and performs collaborative translational research with researchers from the Beatson Institute. He also manages Phase I, II and III trials in the urological cancer field, and is Chief Investigator of the TOUCAN and PLUTO trials (urothelial cancer), SAPROCAN and MAdCaP trials (prostate cancer), and the UK component of the ASPEN trial (renal cell carcinoma). Recently, he has been involved in the COMPARZ trial, which compared pazopanib with sunitinib in renal cell carcinoma patients. He is director of the Glasgow Cancer Research UK Clinical Trials Unit and is an active member of the UK National Cancer Research Institute Clinical Studies Groups in urology.

Item Type:Articles (Other)
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jones, Professor Robert
Authors: Jones, R.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Future Oncology
ISSN:1479-6694
ISSN (Online):1744-8301

University Staff: Request a correction | Enlighten Editors: Update this record